Medoz Pharmacy of Polk, Inc., Davenport, FL
Is Medoz Pharmacy of Polk, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Ceased sterile compounding”.
Does Medoz Pharmacy of Polk, Inc. hold a Florida pharmacy license?
The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH28722 for MEDOZ PHARMACY OF POLK LLC (dba MEDOZ PHARMACY OF POLK), DAVENPORT, status Clear and PH28725 for MEDOZ PHARMACY OF POLK INC. (dba MEDOZ PHARMACY OF POLK), DAVENPORT, status Disc Relinquish. The Colorado State Board of Pharmacy also lists nonresident license OSP 8012 for Medoz Pharmacy of Polk LLC, Davenport, FL, status Active, as of Nov 15, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0004385 for MEDOZ PHARMACY OF POLK LLC, DAVENPORT, FL, status ACTIVE (CURRENT), as of Nov 15, 2026.
Has Medoz Pharmacy of Polk, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Sep 25, 2020), 1 warning letter close-out (Mar 30, 2022), 1 state referral letter (Mar 30, 2022) and 1 FMD-145 letter (Mar 30, 2022) for Medoz Pharmacy of Polk, Inc. State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 5 actions: “Probation Satisfied” dated Feb 25, 2021, case 201800512 on license PH28722, “Voluntary Surrender” dated Jan 7, 2020, case 201910628 on license PH28725 and “Administrative Complaint Filed” dated Jan 17, 2019, case 201800512 on license PH28722, and 2 more listed below. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Medoz Pharmacy of Polk, Inc.
- Location
- Davenport, FL
- Type as FDA labels it
- 503A
- FDA’s note
- Ceased sterile compounding
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Mar 30, 2022
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 14 observations
- State board records
- License found: PH28722, Clear; PH28725, Disc Relinquish
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Medoz Pharmacy of Polk, Inc., a 503A facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Mar 30, 2022 | State referral letter | State Referral Letter Issued 03/30/2022 | Not linked by FDA |
| Mar 30, 2022 | FMD-145 letter | FMD-145 Letter Issued 03/30/2022 | Not linked by FDA |
| Mar 30, 2022 | Warning letter close-out | Warning Letter Close Out Issued 03/30/2022 | Not linked by FDA |
| Aug 27, 2021 | Form 483 | 483 Issued 08/27/2021 | fda.gov |
| Sep 25, 2020 | Warning letter | Warning Letter (09/25/2020) | FDA copy (archived) |
| Aug 9, 2019 | Form 483 | 483 Issued 08/09/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Medoz Pharmacy of Polk Inc, Davenport, FL (FEI number 3015316526), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Aug 27, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3015316526 | 1149926 |
| Aug 9, 2019 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3015316526 | 1099150 |
Form 483s FDA has published for this site
- Aug 27, 2021: Form 483 to Medoz Pharmacy of Polk Inc, published Feb 10, 2022. fda.gov
- Aug 9, 2019: Form 483 to Medoz Pharmacy of Polk Inc, published Nov 12, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 14 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 30, 2019 to Aug 9, 2019: 14 observations
- Firm on the cover
- Medez Pharmacy of Polk Inc, 40230 Highway 27 Ste 100, Davenport, FL 33837-7807
- FEI number
- 3015316526
- Establishment type on the cover
- Producer of Sterile & Non-Sterile Drugs
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitl and, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
You produced hazardous drugs without providing adequate cleaning of work surfaces and cleaning of personnel to prevent cross-contamination.
Specifically, on 10/31/18, according to formulation worksheets, your firm produced <Redacted B4> of Chorionic Gonadotropin (HCG) 1,000U/mL Injection, lot #10312018@7, BUD: 3 Days and <Redacted B4> of Cyclosporin (Corn Oil) New 2% Ophthalmic Solution, lot #10312018@ 10, BUD: 3 Days on the same production day without evidence that cleaning was conducted between batches of hazardous drug products. Both lots were released and dispensed. In addition, your firm failed to identify on the formulation worksheets which ISO 5 BSC <Redacted B4> was used for these hazardous drug products.
Observation 2
Vermin was observed in your production area.
Specifically,
b) Numerous dead ants were observed (7 /30/ 19) along the comers of the walls within the nonsterile suite (where non-sterile dru roducts roduced . According to your firm's Pharmacist, house hold <Redacted B4> ,was used to spray these areas. Your firm's Pharmacist stated he noticed the pest problem approximately three years ago when construction was occurring within close proximity of his facility. During the current FDA Inspection your firm failed to provide pest control records.
Observation 3
Venn in was observed in an area immediately adjacent to your production area.
Specifically,
a) A small dead spider and small dead cockroach were observed (7/30/19) on the anteroom floor ( closest to the bench where gowning occurs).
b) A colony of dead ants were observed (7/30/19) on <Redacted B4> bag containing sterile stoppers located in the unclassified area (adjacent to the anteroom but separated by a door).
c) Colonies of small dead ants and living spiders were observed (7/30/19) on the hallway floors and dead insects observed within the light fixtures leading into the non-sterile suite (where non-sterile drugs are produced).
Observation 4
The ISO 5 classified aseptic processing areas had visibly dirty equipment or surface.
Specifically,
a) Your firm's Bio-Safety CabineaJ <Redacted B4> ISO 5 work surface contained blue stains (resembling stamped ink). On 7 /31/ 19, the blue stains were observed on your Pharmacist's gloves and crimping handle during the production of Methylcobalamin, 5mg/mL injection, lot #07312019@ 1, BUD: 3 Days <Redacted B4> clean room) and Chorionic Gonadotropin (HCG) 1,000U/mL Injection, lot #07312019@3, BUD: 3 Days <Redacted B4> clean room) which can potentially cause product contamination.
b) Your firm's <Redacted B4> clean room (where sterile drug products are produced) contained cracks within the flooring in front of the Biosafety Cabinet Ill which appear difficult to clean and sanitize.
Observation 5
Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.
Specifically,
a) Your firm stores all gowning components in an unclassified area(non-sterile hair net, sterile gloves, nonsterile gown, non-sterile shoe covers, non-sterile sleeve protectors and non-sterile face mask). Your Pharmacist was observed donning the non-sterile hair net, non-sterile shoe covers, and non-sterile face mask within the unclassified area.
c) Within the ISO 7 <Redacted B4> clean room your firm's Pharmacist was observed with his bare hands inside the ISO 5 BSC donning his sterile gloves.
d) Your firm's Pharmacist was observed moving from the ISO 7 <Redacted B4> clean room, through the ISO 8 anteroom and into the ISO 71 clean room without changing his garb. Prior to conducting aseptic operations within the ISO 5 <Redacted B4> BSC your Pharmacist changed his gloves, exposing his hands again to the ISO 5 environment (sleeve protectors were never changed).
Observation 6
Personnel manually contacted the inner surface of the container or closure.
Specifically, your firm's Pharmacist was observed (7/31/19) manually stoppering and of the stoppers with his gloved hands to the vials of Methylcobalamin, Smg/mL <Redacted B4> touching the inner surface lot #07312019@1, BUD: 3 Days clean room). On 8/2/19, Rx <Redacted B4> of Methylcobalamin, Smg/mL injection, lot #07312019@1 was released and shipped.
Observation 7
Personnel did not disinfect and change gloves frequently enough to prevent contamination.
Specifically, your firm's Phannacist was observed (7/31/19) carrying the components into each clean room and touching door handles potentially contaminating his garb and components used during aseptic operations.
Observation 8
HEPA filters were not sealed around each perimeter to the support frame.
Specifically,
a) On 7/3'0/19, your firm's ISO 7 <Redacted B4> clean room contained 1 HEPA ftlter <Redacted B4> to be visually un-clean (HEPA and ceiling around the HEPA appeared stained) and not properly sealed.
b) On 7/30/19 <Redacted B4> your firm's ISO 7 <Redacted B4> clean room contained I HEPA filter <Redacted B4> to contain gaps between the ceiling and HEPA frame making it difficult to properly clean and sanitize and chipping paint surrounding the ceiling frame. In addition, your firm's Pharmacist stated the chipping of paint surrounding the ceiling frame is monitored during his daily cleaning checklist.
Observation 9
Sporicidal agents were not used in your facility's cleanrooms and/or ISO 5 classified aseptic processing area.
Specifically, your firm's Pharmacist stated he cleans the ISO 5 BSC's with only <Redacted B4> . This practice was observed on 7/31/19. Your firm's Pharmacist stated he does not use a sporicidal agent within the ISO 5 BSC's.
Observation 10
Environmental monitoring was not performed in your aseptic processing areas.
Observation 11
IS0-5 classified areas were not certified under dynamic conditions.
Specifically, uni-directional airflow was not verified under operational conditions within your firm's <Redacted B4> clean rooms where sterile products are produced.
Observation 12
Media fills were not performed that closely simulate aseptic production operations incorporating, as appropriate, worst-case activities and conditions that provide a challenge to aseptic operations.
Specifically, your firm's Media fill dated, 6/12/19 fails to closely simulate current aseptic operations. In addition, no environmental and personnel monitoring was conducted during the media fill.
Observation 13
Your firm exposed stock solutions, intended to be sterile, to lower than ISO 5 quality air.
Specifically, I observed (7/30/19) the storage of Tacrolimus 10mg/ML Base C Stock, lot #04262019@3, exp.: 7/25/19 and Alprosla<lil 500 MCG/mL Alcohol Stuck, lul #05012019@2, exp.: I 0/28/19 solutions in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expi1y period.
Observation 14
Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.
Specifically, your firm is utilizing a non-calibrated AND, Model <Redacted B4> balance to weigh active ingredients designated for your firm's non-sterile drug products, therefore lacking assurance if the required amounts are being added to a particular batch.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH28722 | Pharmacy | MEDOZ PHARMACY OF POLK LLC (dba MEDOZ PHARMACY OF POLK) | DAVENPORT | Clear |
| PH28725 | Pharmacy | MEDOZ PHARMACY OF POLK INC. (dba MEDOZ PHARMACY OF POLK) | DAVENPORT | Disc Relinquish |
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Feb 25, 2021: “Probation Satisfied”, license PH28722, case 201800512, MEDOZ PHARMACY OF POLK LLC, DAVENPORT, FL. Board list
- Jan 7, 2020: “Voluntary Surrender”, license PH28725, case 201910628, MEDOZ PHARMACY OF POLK INC., DAVENPORT, FL. Board list
- Jan 17, 2019: “Administrative Complaint Filed”, license PH28722, case 201800512, MEDOZ PHARMACY OF POLK LLC, DAVENPORT, FL. Board list
- Jul 10, 2018: “Probation”, license PH28725, case 201704273, MEDOZ PHARMACY OF POLK INC., DAVENPORT, FL. Board list
- Nov 3, 2017: “Administrative Complaint Filed”, license PH28725, case 201704273, MEDOZ PHARMACY OF POLK INC., DAVENPORT, FL. Board list
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 8012 | OSP | Medoz Pharmacy of Polk LLC | Davenport, FL | Active |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0004385 | NONRESIDENT PHARMACY | MEDOZ PHARMACY OF POLK LLC | DAVENPORT, FL | ACTIVE (CURRENT) |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Connecticut Department of Consumer Protection license file
- Florida Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.